Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases

A rebound of osteoclast activity during the 2 years after a treatment or prevention of osteoporosis with denosumab (Dmab) leads to an increased risk of vertebral fractures (VFs). We attempted to identify the risk factors for these VF and to examine the protective role of bisphosphonates. For that, 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Burckhardt, Peter, Faouzi, Mohamed, Buclin, Thierry, Lamy, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518625/
https://www.ncbi.nlm.nih.gov/pubmed/34009703
http://dx.doi.org/10.1002/jbmr.4335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518625/
https://www.ncbi.nlm.nih.gov/pubmed/34009703
http://dx.doi.org/10.1002/jbmr.4335

Ejemplares similares